Rucaparib

Summarized by Plex Health
Last Updated: 02 May 2022
an evaluation in vitro of parp-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. "an evaluation in vitro of parp-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.", by Nile DL, Rae C, Hyndman IJ, Gaze MN, Mairs RJ. Fig2: The effect of rucaparib and olaparib on PARP-1 activity. Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib...

Rucaparib is used to deal with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Rucaparib is occasionally used for these problems only if your cancer has a specific genetic marker. Rucaparib is also used to deal with prostate cancer with an abnormal BRCA genetics. Rucaparib is provided for this problem when the cancer has infected other parts of the body and surgical procedure or other cancer treatments did not work or have quit working. Rucaparib was authorized for prostate cancer by the U.S. Food and Drug Administration on an "increased" basis. Rucaparib may also be used for purposes not listed in this drug overview. Rucaparib can cause leukemia or serious bone marrow troubles. Utilizing rucaparib may increase your risk of developing major bone marrow issues or other types of cancer, such as leukemia. If the mom or the dad is using rucaparib, Rucaparib can hurt unborn infant. Your doctor may periodically change your dose. Use the medicine exactly as directed. If you take rucaparib for prostate cancer, you might additionally be treated with another medicine called a gonadotropin-releasing hormone, or GnRH. GnRH aids stop the testicles from producing testosterone. If you vomit quickly after taking rucaparib, do not take another dose. Wait until your following arranged dosage to take the medicine again, however do not take 2 dosages at the same time. Your blood will require to be tested usually. Your cancer therapies may be delayed based on the results. Avoid the missed dose and use your following dosage at the normal time.

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.

PubChem - CovalentUnitCount

(Table source)
CIDMolecularFormulaMolecularWeightCanonicalSMILESIsomericSMILESInChIInChIKeyIUPACNameXLogPExactMassMonoisotopicMassTPSAComplexityChargeHBondDonorCountHBondAcceptorCountRotatableBondCountHeavyAtomCountIsotopeAtomCountAtomStereoCountDefinedAtomStereoCountUndefinedAtomStereoCountBondStereoCountDefinedBondStereoCountUndefinedBondStereoCountCovalentUnitCount
9931954C19H18FN3O323.4CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)HMABYWSNWIZPAG-UHFFFAOYSA-N6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one2.5323.14339037323.1433903756.946603332400000001
*** If you want us to remove all links leading to your domain from Plex.page and never use your website as a source of the "Online Knowledge", please contact us using a corporate email and we will remove everything in 10 business days.

logo

Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.